Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia

NCT00104468 is registered in ClinicalTrials.gov with SGX Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00104468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00104468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia
Lead sponsor
SGX Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2003
Completion date
June 30, 2007
Enrollment
50
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia